Environmental chemicals as substrates, inhibitors or inducers of drug transporters: Implication for toxicokinetics, toxicity and pharmacokinetics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 1, 2012, Pages 29-46

  Fardel, Olivier ^a   Kolasa, Elise ^a   Le Vee, Marc ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Drug interactions; Drug transporters; Environmental contaminants; Pharmacokinetics; Toxicity; Toxicokinetics

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; ENVIRONMENTAL CHEMICAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GLYCOPROTEIN P; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PEPTIDE TRANSPORTER 1; PESTICIDE;

HUMAN; NONHUMAN; POLLUTANT; REVIEW; TOXICOKINETICS;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; ENVIRONMENTAL POLLUTANTS; HUMANS; MEMBRANE TRANSPORT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84255167296     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.637918     Document Type: Review

References (184)

1. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003;8(Suppl 2):6-9
2. Sai Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab Pharmacokinet 2005;20:91-9
3. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004;44:137-66 (Pubitemid 38263837)
4. Ueno M, Nakagawa T, Wu B, et al. Transporters in the brain endothelial barrier. Curr Med Chem 2010;17:1125-38
5. Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008;4:923-39
6. Pang KS, Maeng HJ, Fan J. Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm 2009;6:1734-55
7. Leonard GD, Polgar O, Bates SE. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002;3:1652-9 (Pubitemid 36266743)
8. Tirona RG. Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol 2011;373-402
9. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf 2005;28:789-801
10. Glaeser H. Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 2011;285-97
11. Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 2009;5:489-500
12. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
13. Lee EJ, Lean CB, Limenta LM. Role of membrane transporters in the safety profile of drugs. Expert Opin Drug Metab Toxicol 2009;5:1369-83
14. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3-23 (Pubitemid 32830943)
15. Klaassen CD. Xenobiotic transporters: another protective mechanism for chemicals. Int J Toxicol 2002;21:7-12 (Pubitemid 34274779)
16. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-37 (Pubitemid 40552845)
17. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62:1-96
18. Schrenk D, Baus PR, Ermel N, et al. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 2001;120:51-7 (Pubitemid 32375070)
19. Weber R, Gaus C, Tysklind M, et al. Dioxin-and POP-contaminated sites-contemporary and future relevance and challenges: overview on background, aims and scope of the series. Environ Sci Pollut Res Int 2008;15:363-93
20. Abernethy DR, Destefano AJ, Cecil TL, et al. Metal impurities in food and drugs. Pharm Res 2010;27:750-5
21. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 2009;3:195-206
22. Ciarimboli G. Organic cation transporters. Xenobiotica 2008;38:936-71
23. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51 (Pubitemid 46876495)
24. Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica 2008;38:889-935
25. Konig J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol 2011;201:1-28
26. Rubio-Aliaga I, Daniel H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 2008;38:1022-42
27. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 2008;10:311-21
28. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008;38:972-94
29. Young JD, Yao SY, Sun L, et al. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008;38:995-1021
30. Yonezawa A, Inui KI. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and Pharmacogenomics. Br J Pharmacol 2011; In press
31. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27 (Pubitemid 351560534)
32. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996;27:1283-91 (Pubitemid 26419684)
33. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011;201:261-83
34. Lecureur V, Courtois A, Payen L, et al. Expression and regulation of hepatic drug and bile acid transporters. Toxicology 2000;153:203-19
35. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53 (Pubitemid 38294344)
36. Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2006;2:351-66 (Pubitemid 46141403)
37. Fardel O, Jigorel E, Le Vee M, Payen L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed Pharmacother 2005;59:104-14 (Pubitemid 40417519)
38. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 2011;201:299-323
39. Poguntke M, Hazai E, Fromm MF, Zolk O. Drug transport by breast cancer resistance protein. Expert Opin Drug Metab Toxicol 2010;6:1363-84
40. Drenou B, Fardel O, Amiot L, Fauchet R. Detection of P glycoprotein activity on normal and leukemic CD34+ cells. Leuk Res 1993;17:1031-5 (Pubitemid 23358333)
41. van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 2006;27:10-16 (Pubitemid 43063119)
42. Peng KC, Cluzeaud F, Bens M, et al. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 1999;47:757-68
43. Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002;82:193-201 (Pubitemid 34160456)
44. Li P, Wang GJ, Robertson TA, Roberts MS. Liver transporters in hepatic drug disposition: an update. Curr Drug Metab 2009;10:482-98
45. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004;126:322-42 (Pubitemid 38040747)
46. Funk C. The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 2008;4:363-79 (Pubitemid 351728512)
47. Zelcer N, van de Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 2005;102:7274-9 (Pubitemid 40696369)
48. Mennone A, Soroka CJ, Cai SY, et al. Mrp4-/-mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006;43:1013-21 (Pubitemid 43724626)
49. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 2006;290:G640-9
50. Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008;9:597-624 (Pubitemid 351803919)
51. El-Sheikh AA, Masereeuw R, Russel FG. Mechanisms of renal anionic drug transport. Eur J Pharmacol 2008;585:245-55
52. Dutheil F, Jacob A, Dauchy S, et al. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin Drug Metab Toxicol 2010;6:1161-74
53. Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011;8:1332-41
54. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129:349-60 (Pubitemid 39388854)
55. Cisternino S, Rousselle C, Lorico A, et al. Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm Res 2003;20:904-9 (Pubitemid 36628438)
56. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000;876:148-53
57. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306:124-31 (Pubitemid 36734365)
58. Prouillac C, Lecoeur S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab Dispos 2010;38:1623-35
59. Kontaxi M, Echkardt U, Hagenbuch B, et al. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J Pharmacol Exp Ther 1996;279:1507-13 (Pubitemid 27166800)
60. Ose A, Kusuhara H, Endo C, et al. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 2010;38:168-76
61. Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 2006;91:140-9
62. Fehrenbach T, Cui Y, Faulstich H, Keppler D. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 2003;368:415-20 (Pubitemid 37491501)
63. Meier-Abt F, Faulstich H, Hagenbuch B. Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 2004;1664:64-9 (Pubitemid 38829318)
64. Fischer WJ, Altheimer S, Cattori V, et al. Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicol Appl Pharmacol 2005;203:257-63 (Pubitemid 40311872)
65. Lu H, Choudhuri S, Ogura K, et al. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 2008;103:35-45 (Pubitemid 351524475)
66. Feurstein D, Kleinteich J, Heussner AH, et al. Investigation of microcystin congener-dependent uptake into primary murine neurons. Environ Health Perspect 2010;118:1370-5
67. Lu WJ, Tamai I, Nezu J, et al. Organic anion transporting polypeptide-C mediates arsenic uptake in HEK-293 cells. J Biomed Sci 2006;13:525-33
68. Yang CH, Glover KP, Han X. Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. Toxicol Lett 2009;190:163-71
69. Ueo H, Motohashi H, Katsura T, Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 2005;70:1104-13 (Pubitemid 41262086)
70. Cha SH, Sekine T, Fukushima JI, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001;59:1277-86 (Pubitemid 32385197)
71. Cha SH, Sekine T, Kusuhara H, et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 2000;275:4507-12 (Pubitemid 30094696)
72. Tachampa K, Takeda M, Khamdang S, et al. Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci 2008;106:435-43 (Pubitemid 351468596)
73. Nakagawa H, Hirata T, Terada T, et al. Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 2008;103:1-8 (Pubitemid 351874526)
74. Yang CH, Glover KP, Han X. Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol Sci 2010;117:294-302
75. Bakhiya N, Arlt VM, Bahn A, et al. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 2009;264:74-9
76. Chen Y, Zhang S, Sorani M, Giacomini KM. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007;322:695-700 (Pubitemid 47105798)
77. Videmann B, Tep J, Cavret S, Lecoeur S. Epithelial transport of deoxynivalenol: involvement of human P-glycoprotein (ABCB1) and multidrug resistance-associated protein 2 (ABCC2). Food Chem Toxicol 2007;45:1938-47 (Pubitemid 47238207)
78. Tep J, Videmann B, Mazallon M, et al. Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters. Toxicol Lett 2007;170:248-58 (Pubitemid 46710276)
79. Dornetshuber R, Heffeter P, Sulyok M, et al. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol Nutr Food Res 2009;53:904-20
80. De Angelis I, Frigge G, Raimondi F, et al. Absorption of fumonisin B1 and aminopentol on an in vitro model of intestinal epithelium; the role of P-glycoprotein. Toxicon 2005;45:285-91 (Pubitemid 40431272)
81. van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Res 2003;63:6447-52 (Pubitemid 37255195)
82. Liu J, Liu Y, Powell DA, et al. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002;170:55-62 (Pubitemid 34031864)
83. Allen JD, Brinkhuis RF, van Deemter L, et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-6
84. Salerno M, Petroutsa M, Garnier-Suillerot A. The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. J Bioenerg Biomembr 2002;34:135-45 (Pubitemid 34477976)
85. Endo T, Kimura O, Sakata M. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol Appl Pharmacol 2002;185:166-71 (Pubitemid 36062790)
86. Bain LJ, LeBlanc GA. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol 1996;141:288-98 (Pubitemid 26414376)
87. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502 (Pubitemid 24153990)
88. Lecoeur S, Videmann B, Mazallon M. Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. Toxicol Lett 2006;161:200-9 (Pubitemid 43138860)
89. Loe DW, Stewart RK, Massey TE, et al. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 1997;51:1034-41 (Pubitemid 27249137)
90. Leslie EM, Ito K, Upadhyaya P, et al. Transport of the beta -O-glucuronide conjugate of the tobacco-specific carcinogen 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 2001;276:27846-54
91. Tribull TE, Bruner RH, Bain LJ. The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett 2003;142:61-70 (Pubitemid 36369215)
92. Oosterhuis B, Vukman K, Vagi E, et al. Specific interactions of chloroacetanilide herbicides with human ABC transporter proteins. Toxicology 2008;248:45-51
93. Vernhet L, Courtois A, Allain N, et al. Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. FEBS Lett 1999;443:321-5 (Pubitemid 29080819)
94. Vernhet L, Allain N, Bardiau C, et al. Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. Toxicology 2000;142:127-34
95. Vernhet L, Allain N, Payen L, et al. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 2001;61:1387-91 (Pubitemid 32452354)
96. Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 2004;279:32700-8 (Pubitemid 39014729)
97. Carew MW, Leslie EM. Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 2010;31:1450-5
98. Kala SV, Neely MW, Kala G, et al. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 2000;275:33404-8
99. Dijkstra M, Havinga R, Vonk RJ, Kuipers F. Bile secretion of cadmium, silver, zinc and copper in the rat. Involvement of various transport systems. Life Sci 1996;59:1237-46 (Pubitemid 26322921)
100. Tsirulnikov K, Abuladze N, Koag MC, et al. Transport of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, a metabolite of trichloroethylene, by mouse multidrug resistance associated protein 2 (Mrp2). Toxicol Appl Pharmacol 2010;244:218-25
101. Lohitnavy M, Lu Y, Lohitnavy O, et al. A possible role of multidrug resistance-associated protein 2 (Mrp2) in hepatic excretion of PCB126, an environmental contaminant: PBPK/PD modeling. Toxicol Sci 2008;104:27-39 (Pubitemid 351859026)
102. Schrickx J, Lektarau Y, Fink-Gremmels J. Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells. Arch Toxicol 2006;80:243-9
103. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99:15649-54 (Pubitemid 35403986)
104. van Herwaarden AE, Wagenaar E, Karnekamp B, et al. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 2006;27:123-30 (Pubitemid 43025252)
105. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005;26:1754-63 (Pubitemid 41487991)
106. Zedeck MS. Polycyclic aromatic hydrocarbons: a review. J Environ Pathol Toxicol 1980;3:537-67
107. Sreeramulu K, Liu R, Sharom FJ. Interaction of insecticides with mammalian P-glycoprotein and their effect on its transport function. Biochim Biophys Acta 2007;1768:1750-7 (Pubitemid 46890794)
108. Pivcevic B, Zaja R. Pesticides and their binary combinations as P-glycoprotein inhibitors in NIH 3T3/MDR1 cells. Environ Toxicol Pharmacol 2006;22:268-76 (Pubitemid 44441961)
109. Bain LJ, McLachlan JB, LeBlanc GA. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 1997;105:812-18 (Pubitemid 27487771)
110. Shabbir A, DiStasio S, Zhao J, et al. Differential effects of the organochlorine pesticide DDT and its metabolite p, p-DDE on p-glycoprotein activity and expression. Toxicol Appl Pharmacol 2005;203:91-8 (Pubitemid 40248364)
111. Iwakiri T, Okumura M, Matsunaga N, et al. Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes. Eur J Pharmacol 2008;580:19-26
112. Jani M, Makai I, Kis E, et al. Ivermectin interacts with human ABCG2. J Pharm Sci 2011;100:94-7
113. Teo S, Vore M. Mirex exposure inhibits the uptake of estradiol-17 beta(beta-Dglucuronide), taurocholate, and L-alanine into isolated rat hepatocytes. Toxicol Appl Pharmacol 1990;104:411-20 (Pubitemid 20262470)
114. Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 2005;6:309-28 (Pubitemid 41086765)
115. Kohle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009;77:689-99
116. Fardel O, Payen L, Courtois A, et al. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology 2001;167:37-46 (Pubitemid 32830945)
117. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-40
118. Tan KP, Wang B, Yang M, et al. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol 2010;78:175-85
119. van Grevenynghe J, Sparfel L, Le Vee M, et al. Cytochrome P450-dependent toxicity of environmental polycyclic aromatic hydrocarbons towards human macrophages. Biochem Biophys Res Commun 2004;317:708-16 (Pubitemid 38481430)
120. Xu S, Weerachayaphorn J, Cai SY, et al. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol 2010;299:G126-35
121. Fardel O, Lecureur V, Corlu A, Guillouzo A. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. Biochem Pharmacol 1996;51:1427-36 (Pubitemid 26000198)
122. Mathieu MC, Lapierre I, Brault K, Raymond M. Aromatic hydrocarbon receptor (AhR).AhR nuclear translocatorand p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a) pyrene in hepatoma cells. J Biol Chem 2001;276:4819-27
123. Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated upregulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011;25:644-52
124. Schuetz EG, Schuetz JD, Thompson MT, et al. Phenotypic variability in induction of P-glycoprotein mRNA by aromatic hydrocarbons in primary human hepatocytes. Mol Carcinog 1995;12:61-5
125. Jigorel E, Le Vee M, Boursier-Neyret C, et al. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006;34:1756-63 (Pubitemid 44427479)
126. Maher JM, Cheng X, Slitt AL, et al. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005;33:956-62 (Pubitemid 41002777)
127. Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 2008;4:895-908
128. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003;304:223-8 (Pubitemid 36008932)
129. Lemaire G, Mnif W, Pascussi JM, et al. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol Sci 2006;91:501-9 (Pubitemid 43832507)
130. Kiyosawa N, Kwekel JC, Burgoon LD, et al. o,p-DDT elicits PXR/CAR-, not ER-, mediated responses in the immature ovariectomized rat liver. Toxicol Sci 2008;101:350-63
131. Ratajewski M, Walczak-Drzewiecka A, Salkowska A, Dastych J. Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor. Toxicol Lett 2011;205:146-53
132. Sparfel L, Payen L, Gilot D, et al. Pregnane X receptor-dependent and -independent effects of 2-acetylaminofluorene on cytochrome P450 3A23 expression and liver cell proliferation. Biochem Biophys Res Commun 2003;300:278-84 (Pubitemid 38375806)
133. Lecureur V, Guillouzo A, Fardel O. Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Carcinogenesis 1996;17:1157-60 (Pubitemid 26158419)
134. Courtois A, Payen L, Le Ferrec E, et al. Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochem Pharmacol 2002;63:333-41 (Pubitemid 34158834)
135. Cherrington NJ, Hartley DP, Li N, et al. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002;300:97-104 (Pubitemid 34028514)
136. Wang X, Sykes DB, Miller DS. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 2010;78:376-83
137. Baldwin WS, Roling JA. A concentration addition model for the activation of the constitutive androstane receptor by xenobiotic mixtures. Toxicol Sci 2009;107:93-105
138. Agarwala S, Chen W, Cook TJ. Effect of chlorpyrifos on efflux transporter gene expression and function in Caco-2 cells. Toxicol In Vitro 2004;18:403-9 (Pubitemid 38591297)
139. Johnson DR, Klaassen CD. Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicol Sci 2002;67:182-9 (Pubitemid 34746471)
140. Cheng X, Maher J, Dieter MZ, Klaassen CD. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 2005;33:1276-82 (Pubitemid 41196968)
141. Wielandt AM, Vollrath V, Manzano M, et al. Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5-trichlorophenoxyacetic acid in the mouse liver. Biochem J 1999;341(Pt 1):105-11 (Pubitemid 29359053)
142. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009;47:1304-9
143. Cheng Q, Taguchi K, Aleksunes LM, et al. Constitutive activation of nuclear factor-E2-related factor 2 induces biotransformation enzyme and transporter expression in livers of mice with hepatocyte-specific deletion of Kelch-like ECH-associated protein 1. J Biochem Mol Toxicol 2011;25:320-9
144. Singh A, Wu H, Zhang P, et al. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010;9:2365-76
145. Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos 2009;30:345-55
146. Gan N, Sun X, Song L. Activation of Nrf2 by microcystin-LR provides advantages for liver cancer cell growth. Chem Res Toxicol 2010;23:1477-84
147. Li HY, Wu SY, Shi N. Transcription factor Nrf2 activation by deltamethrin in PC12 cells: Involvement of ROS. Toxicol Lett 2007;171:87-98 (Pubitemid 46994730)
148. Vernhet L, Seite MP, Allain N, et al. Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J Pharmacol Exp Ther 2001;298:234-9 (Pubitemid 32574532)
149. Pi J, Qu W, Reece JM, et al. Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res 2003;290:234-45 (Pubitemid 37272168)
150. Chin KV, Tanaka S, Darlington G, et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6
151. Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmiumand reactive oxygen species-induced apoptosis. J Biol Chem 2000;275:1887-96 (Pubitemid 30060813)
152. Maher JM, Aleksunes LM, Dieter MZ, et al. Nrf2-and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 2008;106:319-28
153. Zlender V, Breljak D, Ljubojevic M, et al. Low doses of ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex. Toxicol Appl Pharmacol 2009;239:284-96
154. Habibollahi P, Ghahremani MH, Azizi E, Ostad SN. Multi drug resistance-1 (MDR1) expression in response to chronic diazinon exposure: an in vitro study on Caco-2 cells. Bull Environ Contam Toxicol 2011;86:105-9
155. Lorico A, Bertola A, Baum C, et al. Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice. Biochem Biophys Res Commun 2002;291:617-22 (Pubitemid 34687390)
156. Andersen V, Ostergaard M, Christensen J, et al. Polymorphisms in the
157. Zschiedrich K, Konig IR, Bruggemann N, et al. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009;256:115-20
158. Brunette DM, Katz M. The interactions of benzo(a)pyrene with cell membranes: uptake into Chinese hamster ovary (CHO) cells and fluorescence studies with isolated membranes. Chem Biol Interact 1975;11:1-14
159. Sugano K, Kansy M, Artursson P, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010;9:597-614
160. Gilroy DJ, Carpenter HM, Curtis LR. Chlordecone pretreatment alters [14C] chlordecone and [14C]cholesterol transport kinetics in the perfused rat liver. Fundam Appl Toxicol 1994;22:286-92 (Pubitemid 24089173)
161. Myllynen P, Kummu M, Kangas T, et al. ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) in perfused term human placenta. Toxicol Appl Pharmacol 2008;232:210-17
162. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005;11:127-9 (Pubitemid 40321346)
163. Elliott A, Adams J, Al-Hajj M. The ABCs of cancer stem cell drug resistance. IDrugs 2010;13:632-5
164. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627-35 (Pubitemid 32179943)
165. Jansen J, Friesema EC, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid 2005;15:757-68 (Pubitemid 41339256)
166. Blokzijl H, van Steenpaal A, Vander Borght S, et al. Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J Biol Chem 2008;283:35630-7
167. Beedholm-Ebsen R, van de Wetering K, Hardlei T, et al. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood 2010;115:1632-9
168. Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 2009;5:1469-81
169. Lecureur V, Ferrec EL, NDiaye M, et al. ERK-dependent induction of TNFalpha expression by the environmental contaminant benzo(a) pyrene in primary human macrophages. FEBS Lett 2005;579:1904-10 (Pubitemid 40404029)
170. Mollenhauer MA, Bradshaw SG, Fair PA, et al. Effects of perfluorooctane sulfonate (PFOS) exposure on markers of inflammation in female B6C3F1 mice. J Environ Sci Health A Tox Hazard Subst Environ Eng 2011;46:97-108
171. Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 2008;36:217-22 (Pubitemid 351185762)
172. Stockmann-Juvala H, Alenius H, Savolainen K. Effects of fumonisin B(1) on the expression of cytokines and chemokines in human dendritic cells. Food Chem Toxicol 2008;46:1444-51
173. Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 2009;37:685-93
174. Le Vee M, Jouan E, Moreau A, Fardel O. Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. Fundam Clin Pharmacol 2011;25:99-103
175. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36:205-16 (Pubitemid 351185732)
176. von Wedel-Parlow M, Wolte P, Galla HJ. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem 2009;111:111-18
177. Petrovic V, Wang JH, Piquette-Miller M. Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab Dispos 2008;36:1944-50
178. Forster F, Volz A, Fricker G. Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. Eur J Pharm Biopharm 2008;69:396-403 (Pubitemid 351467166)
179. van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 2005;1:175-85
180. Stamatelos SK, Brinkerhoff CJ, Isukapalli SS, Georgopoulos PG. Mathematical model of uptake and metabolism of arsenic(III) in human hepatocytes -Incorporation of cellular antioxidant response and threshold-dependent behavior. BMC Syst Biol 2011;5:16
181. Dix DJ, Houck KA, Martin MT, et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 2007;95:5-12 (Pubitemid 44942773)
182. Rotroff DM, Beam AL, Dix DJ, et al. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J Toxicol Environ Health B Crit Rev 2010;13:329-46
183. Kroetz DL, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther 2010;87:109-16
184. Hodgson E, Rose RL. Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol 2007;21:182-6 (Pubitemid 350194378)